Jingshan Shen
jsshen@mail.shcnc.ac.cn
Chinese, English
Shanghai
University of Chinese Academy of Sciences
Medical School
  • 1995-09--1998-07 PhD in Organic Chemistry: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  • 1998-08~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher, Group Leader
  • 1995-09~1998-07 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - PhD in Organic Chemistry
  • Shanghai Excellent Invention Gold Award (2024): 35th Shanghai Excellent Invention Selection
  • Advanced Worker (2024): 3rd 'Outstanding Role Model Around You' of Shanghai Branch, Chinese Academy of Sciences
  • Lihuayi Chemical Innovation Award (2023): 1st Chinese Chemical Society
  • Excellent Supervisor (2023): Chinese Academy of Sciences
  • Most Beautiful Science Worker in Shanghai (2022): Shanghai
  • Top Ten Scientific and Technological Innovations (2022): Shanghai Branch, Chinese Academy of Sciences
  • May Fourth Youth Commando (2021): Shanghai Branch, Chinese Academy of Sciences
  • State Council Special Government Allowance (2019): State Council
  • Outstanding Role Model Around You (2019): Shanghai Branch, Chinese Academy of Sciences
  • Shanghai Staff Rationalization Construction Innovation Award (2018): Shanghai
Drug Chemistry
Drug Synthesis Route Research
  • An Alternative Approach to Synthesize Sildenafil via Improved Copper-Catalyzed Cyclization, Jingshan Shen, 2024
  • Impurity study of tecovirimat, Jingshan Shen, 2024
  • An Improved Iodine-Catalyzed Aromatization Reaction and Its Application in the Synthesis of a Key Intermediate of Cannabidiol, Jingshan Shen, 2024
  • Combination of miR159 Mimics and Irinotecan Utilizing Lipid Nanoparticles for Enhanced Treatment of Colorectal Cancer, Jingshan Shen, 2024
  • Direct esterification of amides by the dimethylsulfate-mediated activation of amide C-N bonds, Jingshan Shen, 2024
  • Cannabidiol exhibits anxiolytic-like effects and antipsychotic-like effects in mice models, Jingshan Shen, 2024
  • Oral Simnotrelvir for Adult Patients with Mild-to-Moderate Covid-19, Jingshan Shen, 2024
  • Discovery of a CB2 and 5-HT1A receptor dual agonist for the treatment of depression and anxiety, Jingshan Shen, 2024
  • Improved and ligand-free copper-catalyzed cyclization for an efficient synthesis of benzimidazoles from o-bromoarylamine and nitriles, Jingshan Shen, 2024
  • An efficient synthesis of the last step key intermediate for telmisartan via Pd-catalyzed carbonylative cyclization, Jingshan Shen, 2023
  • Optimized Synthesis of the Key Intermediate of Telmisartan via the Cyclization of 2-Bromoarylamine with n-Butyronitrile, Jingshan Shen, 2023
  • Glimepiride, a novel soluble epoxide hydrolase inhibitor, protects against heart failure via increasing epoxyeicosatrienoic acids, Jingshan Shen, 2023
  • Design, synthesis and biological evaluation of covalent peptidomimetic 3CL protease inhibitors containing nitrile moiety, Jingshan Shen, 2023
  • Synthesis and evaluation of NHC derivatives and 4'-fluorouridine prodrugs, Jingshan Shen, 2023
  • Design, synthesis and biological evaluation of peptidomimetic benzothiazolyl ketones as 3CLpro inhibitors against SARS-CoV-2, Jingshan Shen, 2023
  • Synthesis, cytotoxicity, and pharmacokinetic evaluations of niclosamide analogs for anti-SARS-CoV-2, Jingshan Shen, 2023
  • Structure-based development and preclinical evaluation of SARS-CoV-2 3C-like protease inhibitor simnotrelvir, Jingshan Shen, 2023
  • Efficient Large-Scale Process for Tecovirimat via Reactive Distillation for the Preparation of Cycloheptatriene, Jingshan Shen, 2023
  • A viral RNA-dependent RNA polymerase inhibitor VV116 broadly inhibits human coronaviruses and has synergistic potency with 3CLpro inhibitor nirmatrelvir, Jingshan Shen, 2023
  • Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial, Jingshan Shen, 2023
  • Preventive and therapeutic benefits of nelfinavir in rhesus macaques and human beings infected with SARS-CoV-2, Jingshan Shen, 2023
  • Optimized Synthesis of a Key Intermediate of Nirmatrelvir, Jingshan Shen, 2023
  • TPN171片在中国老年受试者中的安全性及药动学Ⅰ期临床研究, 沈敬山, 2023
  • Pharmacokinetics, mass balance, and metabolism of [14C] TPN171, a novel PDE5 inhibitor, in humans for the treatment of pulmonary arterial hypertension, Jingshan Shen, 2023
  • Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog SARS-CoV-2, in Chinese healthy subjects, Jingshan Shen, 2022
  • Synthesis and biological evaluation of artemisinin derivatives as potential MS agents, Jingshan Shen, 2022
  • A novel synthesis of tetrahydrocortisone 3-glucuronide, Jingshan Shen, 2022
  • One-pot synthesis of molnupiravir from cytidine, Jingshan Shen, 2022
  • Synthesis and antiviral activity of 2'-deoxy-6'-substituted carbocyclic nucleosides, Jingshan Shen, 2022
  • Synthesis and biological evaluation of artemisinin derivatives as potential MS agents, Jingshan Shen, 2022
  • Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model, Jingshan Shen, 2022
  • An improved and practical synthesis of rivaroxaban, Jingshan Shen, 2022
  • Chemo- and site-selective lysine modification of peptides and proteins under native conditions using the water-soluble zolinium, Jingshan Shen, 2022
  • Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2, Jingshan Shen, 2021
  • A phase I study to evaluate the safety, tolerability, and pharmacokinetics of TPN171H, a novel phosphodiesterase type 5 inhibitior, in healthy subjects, Jingshan Shen, 2021
  • Scalable Process of Making 5, 7-Dichloro-tetrahydroisoquinoline-6-carboxylic Acid Using Methylene as the Protecting Group, Jingshan Shen, 2021
  • Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2, Jingshan Shen, 2021
  • TPN672: A Novel Serotonin-Dopamine Activity Modulator for the Treatment of Schizophrenia, Jingshan Shen, 2021
  • Virus In Vitro by Remdesivir, Its Parent Nucleoside and β-D-N4-hydroxycytidine, Jingshan Shen, 2021
  • Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate, Jingshan Shen, 2021
  • Chronic administration of synthetic cannabidiol induces antidepressant effects involving modulation of serotonin and noradrenaline levels in the hippocampus, Jingshan Shen, 2021
  • 9,10-Anhydrodehydroartemisinin Attenuates Experimental Autoimmune Encephalomyelitis by Inhibiting Th1 and Th17 Cell Differentiation, Jingshan Shen, 2021
  • SARS-CoV-2 envelope protein causes acute respiratory distress syndrome (ARDS)-like pathological damages and constitutes an antiviral target, Jingshan Shen, 2021
  • Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC-MS/MS, Jingshan Shen, 2021
  • 抗新冠肺炎药物研究进展, 沈敬山, 2021
  • Significant Inhibition of Porcine Epidemic Diarrhea Virus In Vitro by Remdesivir, Its Parent Nucleoside and β-d-N-4-hydroxycytidine, Jings
Drug Chemistry Pharmaceuticals Organic Chemistry Synthesis Medicinal Chemistry Drug Development Chemical Synthesis Pharmacology Biochemistry Molecular Biology

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.